key: cord-1012541-9mtux4ck
authors: Singh, Anupam Kumar; Jena, Anuraag; Kumar‐M, Praveen; Sharma, Vishal; Sebastian, Shaji
title: Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta‐analysis
date: 2021-03-23
journal: United European Gastroenterol J
DOI: 10.1177/2050640620972602
sha: b8e52c72dab68040e9ff38e6444ac3274ff4c15d
doc_id: 1012541
cord_uid: 9mtux4ck

BACKGROUND: The risk of severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2) infection and clinical outcomes of coronavirus disease (COVID‐19) in inflammatory bowel disease are unclear. METHODS: We searched PubMed and Embase with the keywords: inflammatory bowel disease, Crohn's disease, ulcerative colitis and COVID‐19, novel coronavirus and SARS‐CoV‐2. We included studies reporting the frequency of COVID‐19 infection and outcomes (hospitalisation, need for intensive care unit care and mortality) in patients with inflammatory bowel disease. We estimated the pooled incidence of COVID‐19 in inflammatory bowel disease and comparative risk vis‐a‐vis the general population. We also estimated the pooled frequency of outcomes and compared them in patients who received and did not receive drugs for inflammatory bowel disease. RESULTS: Twenty‐four studies were included. The pooled incidence rate of COVID‐19 per 1000 patients of inflammatory bowel disease and the general population were 4.02 (95% confidence interval [CI, 1.44–11.17]) and 6.59 [3.25–13.35], respectively, with no increase in relative risk (0.47, 0.18–1.26) in inflammatory bowel disease. The relative risk of the acquisition of COVID‐19 was not different between ulcerative colitis and Crohn's disease (1.03, 0.62–1.71). The pooled proportion of COVID‐19‐positive inflammatory bowel disease patients requiring hospitalisation and intensive care unit care was 27.29% and 5.33% while pooled mortality was 4.27%. The risk of adverse outcomes was higher in ulcerative colitis compared to Crohn's disease. The relative risks of hospitalisation, intensive care unit admission and mortality were lower for patients on biological agents (0.34, 0.19–0.61; 0.49, 0.33–0.72 and 0.22, 0.13–0.38, respectively) but higher with steroids (1.99, 1.64–2.40; 3.41, 2.28–5.11 and 2.70, 1.61–4.55) or 5‐aminosalicylate (1.59, 1.39–1.82; 2.38, 1.26–4.48 and 2.62, 1.67–4.11) use. CONCLUSION: SARS‐CoV‐2 infection risk in patients with inflammatory bowel disease is comparable to the general population. Outcomes of COVID‐19‐positive inflammatory bowel disease patients are worse in ulcerative colitis, those on steroids or 5‐aminosalicylates but outcomes are better with biological agents.

The coronavirus disease (COVID-19) pandemic has brought forth a multitude of challenges for patients having inflammatory bowel disease (IBD) and healthcare practitioners involved in the care of patients with IBD. IBDs, both ulcerative colitis (UC) and Crohn's disease (CD), are associated with an increased risk of infections, especially in elderly patients, active IBD and those on immunosuppressive medications. 1 In many regions, national-wide lockdowns have had effects on the availability of drugs and access to healthcare. To add to this, patients have faced psychological problems such as anxiety because of the concerns about their health in the presence of underlying IBD and ongoing treatment with immunosuppressive drugs. 2 While COVID-19 has high infectivity and carries the risk of significant morbidity and mortality, information on the risk of infection by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in IBD patients and the outcomes is limited.

Angiotensin-converting enzyme 2 (ACE-2) receptor, which has a role in viral entry into host cells, is expressed in the human intestine and the expression could be upregulated after infection with SARS-CoV-2. There are conflicting data on changes in the expression of ACE-2 in ileal and colonic mucosa of patients with active IBD. 3, 4 In addition, the therapeutic agents used in IBD could affect ACE-2 expression. 4 Therefore, a complex interplay of receptors, physiological processes and therapies may define the risk of acquisition and clinical outcomes in these patients.

Furthermore, published evidence regarding the risk of the acquisition of coronaviruses and clinical outcomes in infected patients with IBD was unavailable prior to this pandemic. Various organisations, in this state of evidence vacuum, have provided expert consensus-based guidance for clinicians and patients with IBD. 5 The published literature on IBD and COVID-19 is limited by cohort studies and case series including a small number of patients. This makes it difficult to assess the actual risk of COVID-19 infection in patients with IBD and the consequences of such an infection. Another important concern is the effect of various therapeutic agents used in IBD on the risk of acquisition and the clinical course of COVID-19.

Therefore, we planned to do a systematic review of observational studies on the risk of the acquisition of SARS-CoV-2 in patients with IBD, and to estimate whether the drugs affect the risk of acquisition and outcomes of SARS-CoV-2 infection.

This meta-analysis was conducted in accordance with the Meta-Anal-

Reporting Items for Systematic Reviews and Meta-Analyses guidance.

We searched electronic databases using PubMed and Embase from 1 December 2019 to 29 July 2020. The keywords used for the search were inflammatory bowel disease, ulcerative colitis, Crohn disease, Crohn's disease combined using the operator "AND" Coronavirus, COVID-19, SARS-COV-2, nCOV, coronaviridae infection or coronavirus disease 2019 (detailed strategy as described in Table S1 ). The bibliographies of included studies and reviews were searched for additional eligible studies. The authors of unpublished data of which we were aware were contacted for data. The eligible titles were combined and the duplicates were removed. The titles and abstracts were then reviewed by two reviewers (Anupam Kumar Singh and Anuraag Jena). After screening of the titles and abstracts, papers were selected for full text screening. Differences, if any, were resolved after discussion with a third reviewer (Vishal Sharma).

We included all relevant articles which fulfilled the inclusion criteria irrespective of the type (original paper, abstract, letter, correspondence), format or the language of publication. We included studies which reported at least one of the two key outcomes: (a) risk or frequency of acquisition of SARS-CoV-2 infection in IBD patients with or without comparison to the general population; or (b) outcomes (hospitalisation, need for intensive care unit (ICU) care or mortality) in IBD patients infected with SARS-COV-2. We excluded studies which did not have relevant outcome data or the data were incomplete. We also excluded single patient case reports, reviews, editorial and commentaries.

Data were extracted from the included studies by the two reviewers (Anupam Kumar Singh and Anuraag Jena) and any discrepancy was resolved by discussion with the third reviewer (Vishal Sharma).

Extracted data included publication details (author and year), place of study, overall population of IBD patients and COVID-19-positive IBD patients, age, gender, disease type (CD or UC), presence of comorbidities, current treatment including 5-aminosalicylic acid (5-ASA), immunomodulators (thiopurines, calcineurin inhibitors and methotrexate), steroids, biological agents (antitumour necrosis factor [TNF], vedolizumab and ustekinumab) and small molecule inhibitors and details of their outcomes (hospitalisation, need for ICU and mortality). The definitions of COVID-19 infection used in various studies were also recorded.

The analysis was conducted using R statistical software version 4.0.1 and meta package was used additionally. The inverse variance method with a random-effect approach was used for computing the pooled summary of incidence. The incidence was logit transformed for computing summary and the Clopper-Pearson confidence interval was used for individual studies. Similarly, the overall risk ratio was computed by the inverse variance method with a random effect approach. Continuity correction of 0.5 was applied for cells with 0 value. The heterogeneity was determined by I 2 and p value of heterogeneity. The DerSimonian-Laird estimator was used for computing τ. 2 We used a random-effect approach irrespective of I 2 considering that heterogeneity was present among the studies at the level of study design and approach towards the research question.

We calculated the pooled incidence of COVID-19 infection in patients with IBD and in the general population. We calculated the pooled risk ratio of acquisition of COVID-19 in IBD as compared to the general population. Among the IBD population, the risk of acquiring the COVID-19 infection was assessed for the subtype of IBD; that is, UC and CD. We also did subgroup analysis for assessing the impact of the age of patients on the incidence of COVID-19 in IBD patients based on a cut-off of 45 years. We also calculated the risk of infection in IBD patients based on the medication used for the treatment of IBD infection. For the purpose of analysis, the thiopurines, calcineurin inhibitors and antimetabolites (methotrexate) were grouped together as immunomodulators.

We estimated the pooled frequency of various outcomes of interest: hospitalisation, need for ICU care and mortality in the patients with IBD infected with COVID-19 and similarly for the subtypes of IBD (UC and CD) and the pooled risk of each outcome in patients receiving or not receiving various medications used for the treatment of IBD (5-ASA, immunomodulators, steroids and biological agents). In the outcome analysis, the biological agents (anti-TNF, vedolizumab and ustekinumab) were clubbed together as "biologics". The risk ratio was calculated for hospitalisation, need for ICU and mortality in patients with UC and CD infected with COVID-19. For the outcomes which were found to be heterogeneous (I 2 > 50%), assessment of heterogeneity by the Baujat plot and leave-one-out analysis was done.

independently assessed the methodological quality and risk of bias for each study. We used the Joanna Briggs Institute critical appraisal checklist for studies reporting the incidence and outcome data. 6 

After the database search a total of 390 titles were identified and two additional papers were identified from other sources. In all there were 157 duplicates. Therefore, a total of 235 articles were screened for title and abstract and 35 papers underwent full text screening ( Figure 1 ). Eventually, data from 24 studies were used for analysis.

This also includes data extracted from the SECURE-IBD registry (on 29 July 2020) and one study identified by manual search. Table 1 provides the details of the included studies including location, number of subjects, age, basis of diagnosis, comorbidities and the eventual inclusion in one of the two analyses. 2, 8, 29 The definitions used for COVID diagnosis were based on real time polymerase chain reaction (RT-PCR) testing or clinical symptoms consistent with COVID-19

with radiological evidence of pneumonia in most studies (Table 1) . 

Seventeen studies provided the information on the incidence rate of Figure 2 ). For studies in which the mean/median age of IBD patients was provided, we calculated the pooled incidence of COVID separately for studies with a mean/median age of 45 years or less and over 45 years. While the pooled incidence in studies with a mean/median age of 45 years or less was 2.06% (0.77-5.54; I 2 = 18), it was 4.44% (0.99-19.61; I 2 = 96%) for the studies with an age over 45 years ( Figure S1 ). In addition, the studies which provided information on the impact of age on COVID-19 infection in IBD are shown in Table S3 .

The overall incidence of COVID-19 in patients with UC was 4.55 (0.76-26.80; I 2 = 93%) per 1000 cases ( Figure S2 ). The overall incidence rate of COVID-19 in patients with CD was 6.66 (1.4929.35; I 2 = 92%) per 1000 cases ( Figure S2 ). When the nine studies reporting the risk in UC and CD were compared for the overall RR, the risk was not different between the two (RR 1.03, 0.62-1.71; I 2 = 0; Figure S2 ). 

The hospitalisation rates in the 11 included studies varied from 0% to 66.67%. The pooled hospitalisation rate was 27.99% (21.92-34.99 ; Figure 4 ). The pooled proportion of patients needing ICU care was 5.33%

(4.46-6.36; I 2 = 0) based on data from nine studies (Figure 4) . The pooled mortality rate in patients with IBD with COVID-19 was 4.27%

(2.39-7.53; I 2 = 51%) and mortality rates varied from 0% to 33.3% in the 13 studies which were included (Figure 4 ).

The overall risk of hospitalisation was higher in patients with UC (RR 1.55, 1.22-1.97; I 2 = 15%) ( Figure 5 ).

The risk of need for ICU care was statistically similar between the two groups (RR 1.42, 0.972.07; I 2 = 0%; Figure 5 ). However, the risk of mortality was higher in patients with UC infected with COVID-19 as compared to CD (RR 1.94, 1.22-3.10; I 2 = 0%; Figure 5 ).

The relative risk of hospitalisation ( I 2 = 0) were higher with the use of 5-ASA ( Figure 6 ). The RR of 

The heterogeneity assessment was conducted for the incidence of COVID-19 among the IBD and general population and outcome assessment (mortality and hospitalisation) among the patients with IBD with COVID-19. The leave-one-out analysis for the incidence of COVID-19 among IBD and the general population did not lead to a significant change in heterogeneity. The detailed information is provided in Figures S3 and S4 .

Heterogeneity: Tau 2 = 0; Chi 2 = 1.07, df = 2 (P = 0.59); I 2 = 0% Gubatan -169

The risk of bias of included studies for the incidence of COVID-19

infection and the outcomes of COVID-19 infection in IBD patients is summarised in Tables S4 and S5. As the Joanna Briggs guidance suggests against using a score cut-off for quality assessment we also did not score the studies. 30 

Hospitalization ASA F I G U R E 6 The pooled relative risk of various outcomes (hospitalisation, need for ICU and mortality) in IBD COVID patients with respect to the use of various drugs (5-ASA, steroids, immunomodulators, biological agents, anti-TNF, vedolizumab and ustekinumab). The pooled summary was computed by a random effect approach. 5-ASA, aminosalicylic acid; CI, confidence interval; IBD, inflammatory bowel disease; ICU, intensive care unit; TNF, tumour necrosis factor SINGH ET AL. The findings of the present meta-analysis suggest that the risk of COVID-19 in IBD is not different from the general population.

The risk of acquisition also does not seem to be affected by the type of IBD; that is, UC or CD. Furthermore, the risk of acquisition -173 of COVID-19 in IBD is not affected by the drugs used for treatment of IBD except for 5-ASA. In COVID-19-positive patients with IBD, hospitalisation was needed in 27% of patients while the mortality rate was under 5%. The risk of adverse outcomes (hospitalisation and mortality) were higher in patients with UC.

The use of 5-ASA or steroids was also associated with adverse outcomes (hospitalisation, ICU admission and mortality) while biological agents were protective.

The increased risk of adverse outcomes in UC as compared to CD could be due to the fact that patients with UC are more likely to be of older age. The usage of various drugs is also likely to be different in UC and CD, with patients having UC being more likely to receive 5-ASA whereas those with CD are more likely to receive biological agents. 34 It is also unclear if biological differences in the two conditions, including the differences in expression of ACE-2 and transmembrane protease serine-2, could be responsible for differences in the outcomes. 3, 4 The reasons for the increased risk of COVID-19 infection with 5-ASA are unclear but this may be related to the fact that 5-ASA use may be a proxy for underlying UC. It has been shown that the expression of ACE-2 receptor is increased to a larger degree in patients with UC. 3 In addition, a higher proportion of older IBD patients have UC and hence are more likely to be tested due to a higher likelihood of symptomatic disease.

Another notable finding is the association of drugs used in IBD with clinical outcomes following COVID-19. While the use of 5-ASA and steroids was associated with an increased risk of hospitalisation, ICU admission and mortality, the use of biological agents was associated with a reduction in these outcomes. These findings support the recommendations of various expert groups to limit the use of steroids and lower the dosages in the setting of the pandemic.

Conversely, dexamethasone has been shown in a well-powered randomised study (RECOVERY trial) to improve the outcomes in patients with severe COVID disease. Therefore, the findings of our meta-analysis could represent the fact that steroid use is a proxy for the subset of patients with active IBD who are predisposed to adverse outcomes. Another finding is that 5-ASA use is associated with adverse outcomes, which is difficult to explain by the biological action of 5-ASA. 5-ASA acts through peroxisome proliferatoractivated receptor-γ which should attenuate the inflammatory response. However, 5-ASA use could be an indicator of underlying UC and active disease and thereby associated with adverse outcomes. Finally, the use of biological agents was associated with a reduction in adverse outcomes. Because of the limited number of studies, we did not stratify this comparison for various groups of biological agents. However, it has been suggested that anti-TNF could be beneficial in COVID-19 disease by attenuating the hyperinflammatory response known as cytokine storm. 35 The drug, anecdotally, has been shown to be efficacious in improving COVID-19 disease and is subject to a controlled trial.

This systematic review provides some guidance for the care of these patients and suggests that steroid use may be avoided in the setting of the pandemic while the use of biological agents can be continued. Furthermore, with the potential of new surges in various locations, the results of our meta-analysis could guide clinicians and patients regarding the continuation of IBD medication in such scenarios. However, the results of this study should be looked at taking into consideration the limitations. Incidence in the included studies is reported from different geographical locations with different genetic composition of the population, medication used for IBD, comorbidities and hygiene practices, which may affect the underlying risk of acquisition of SARS-CoV-2 infection. Also, some studies evaluated only the symptomatic individuals for COVID-19. Because of the limited availability of data, the confounding effect of older age, comorbidities, active disease and the combination of IBD medications on the risk of COVID-19 acquisition and outcome could not be evaluated. In particular, one study which evaluated the age standardised incidence of COVID in IBD patients suggested that the risk in the IBD population may be overestimated. 8 Unfortunately, as similar data were not available from other studies, an analysis to account for differences of risk with age could not be performed. However, analysis from studies with a mean age of less than 45 years or over 45 years suggests that the incidence of COVID was higher in studies with a greater mean age. Furthermore, as SECURE-IBD are registrybased data, there may be a risk of the duplication of data. Also, the number of studies was limited especially for some analyses like the effect of various drug treatments on the outcomes. To conclude, the present meta-analysis suggests that the risk of COVID in IBD patients is not higher than the general population.

Also, the outcomes of COVID in IBD may be adversely affected by the type of disease (UC) and the use of 5-ASA or steroids. The use of biological agents, in contrast, seems to be associated with better outcomes.

The authors declare that there are no conflict of interests.

Not applicable as the paper is a systematic review and did not involve any primary research. 

The data are available upon reasonable request to the corresponding author.

Not applicable as the paper does not involve primary research on human subjects.

https://orcid.org/0000-0003-2472-3409

Shaji Sebastian https://orcid.org/0000-0002-3670-6545

Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases

A cross-sectional survey on the psychological impact of the COVID-19 pandemic on inflammatory bowel disease patients in Saudi Arabia

Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease

Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD

International Organization for the Study of Inflammatory Bowel Disease. Management of patients with Crohn's disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting

Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data

Joanna Briggs Institute Reviewer's Manual. The Joanna Briggs Institute

Novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

Are there any association between COVID-19 severity and immunosuppressive therapy?

Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease

Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque country

Covid-19 in immune-mediated inflammatory diseases--case series from New York

) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition

From the American Epicenter: coronavirus disease 2019 in patients with inflammatory bowel disease in the New York City metropolitan area

Impact of anti-TNF and thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: a nationwide VA cohort. study

Impact of COVID-19 pandemic on the daily management of bio-technological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre

Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

Inflammatory bowel disease in the COVID-19 pandemic -the patients' perspective

Low frequency of COVID-19 in inflammatory bowel diseases

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of coronavirus disease

Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China

Risk of severe COVID-19 in patients with inflammatory bowel disease in United States. A multicenter research network study

SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California

Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 outbreak in Northern Italy

Zero COVID-19 infection in inflammatory bowel disease patients: findings from populationbased inflammatory bowel disease registries in Hong Kong and Taiwan

Keeping on the high quality of healthcare in Greek inflammatory bowel disease patients in the SARS-CoV-2 era

Inflammatory bowel diseases and biological treatment in SARS-CoV-2 era. Why not?

SECURE-IBDDatabase Public Data Update

Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database System Rev Implement Rep

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Imbalance of the reninangiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. United